The aim of the trial was to study the efficacy and safety of the ointment containing mupirocin 2% and betamethasone dipropionate 0.05% in the treatment of infected dermatoses. Patients having either primary infection complicated by dermatoses or dermatoses infected secondarily were included in their study. From the analysis of 59 patients, it was noted that this ointment was found to be safe and very effective by dermatologist in the treatment of infected dermatoses in 94.9% of the patients. Similarly 89.8% of the patients reported more than 70% improvement in their symptoms after 7 days of treatment. No adverse effects were reported during the treatment period by any of the patients except worsening of skin lesions by one patient.